药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Potassium cation
Ecopipam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ecopipam.
Potassium cation
Cerlapirdine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Cerlapirdine.
Potassium cation
Gepirone
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Gepirone.
Potassium cation
Eplivanserin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Eplivanserin.
Potassium cation
Sarpogrelate
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Sarpogrelate.
Potassium cation
Vinpocetine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Vinpocetine.
Potassium cation
MK-212
The risk or severity of adverse effects can be increased when Cannabidiol is combined with MK-212.
Potassium cation
m-Chlorophenylpiperazine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with m-Chlorophenylpiperazine.
Potassium cation
Imagabalin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Imagabalin.
Potassium cation
Tetrahydropalmatine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Tetrahydropalmatine.
Potassium cation
Vabicaserin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Vabicaserin.
Potassium cation
Idalopirdine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Idalopirdine.
Potassium cation
Lanicemine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lanicemine.
Potassium cation
Etiracetam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Etiracetam.
Potassium cation
Brexanolone
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Brexanolone.
Potassium cation
Tetrahydrocannabivarin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Tetrahydrocannabivarin.
Potassium cation
Tropisetron
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Tropisetron.
Potassium cation
Iferanserin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Iferanserin.
Potassium cation
Mosapride
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Mosapride.
Potassium cation
Psilocybin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Psilocybin.